Artificial scab for use in an airway

Patent metadata

Field	Value
Publication number	US-9700648-B2
Application number	US-201113282332-A
Country	US
Kind code	B2
Filing date	Oct 26, 2011
Priority date	Oct 27, 2010
Publication date	Jul 11, 2017
Grant date	Jul 11, 2017

Abstract

Body tissue and structures in an airway may be treated with an artificial scab comprising an inhomogeneous, uncohesive, solid sheet-like body comprising a granular mixture of chitosan and polysaccharide particles. The artificial scab breaks apart into smaller pieces if peeled away from the surgical site or wound, thus reducing the risk of airway occlusion.

First claim

We claim:

1. A composition comprising a substantially dry, free-flowing powdered mixture of about 10 to about 90 wt. % at least partially solvatable chitosan particles containing amino groups and about 90 to about 10 wt. % at least partially solvatable oxidized polysaccharide particles containing aldehyde groups, which mixture is sterilized and in sealed packaging and wherein the amino group functionality and molecular weight of the chitosan and the aldehyde group functionality and molecular weight of the oxidized polysaccharide are such that the particles when deposited onto a surgical site or wound moistened with bodily fluids will adhere to such site or wound and will adhere to one another by inter-particle crosslinking reaction of amino groups on the chitosan particles with aldehyde groups on the polysaccharide particles, and thereby form an uncohesive, solid sheet-like body having an inhomogeneous surface appearance and an inhomogeneous internal structure that breaks apart into smaller pieces if peeled away from the surgical site or wound, wherein substantially dry means the powder contains less than 10 wt. % water.

2. A composition according to claim 1 wherein the substantially dry, free-flowing powdered mixture contains less than 5 wt. % water.

3. A composition according to claim 1 wherein the chitosan comprises a high molecular weight chitosan.

4. A composition according to claim 1 wherein the chitosan comprises a salt.

5. A composition according to claim 1 wherein the chitosan comprises a glutamate salt.

6. A composition according to claim 1 wherein the oxidized polysaccharide comprises oxidized cellulose, chitin, chitosan, chondroitin sulfate, dextran, glycogen or hyaluronic acid.

7. A composition according to claim 1 wherein the oxidized. polysaccharide comprises oxidized starch.

8. A composition according to claim 1 wherein the chitosan and oxidized polysaccharide are combined in a ratio of about 3:1 to about 1:5.

9. A composition according to claim 1 containing about 20 to about 80 wt. % chitosan and about 80 to about 20 wt. % oxidized polysaccharide.

10. A composition according to claim 1 containing about 30 to about 70 wt. % chitosan and about 70 to about 30 wt. % oxidized polysaccharide.

11. A composition according to claim 1 further comprising an antimicrobial agent.

12. A composition according to claim 1 further comprising an analgesic, anti-cholinergic, anti-fungal agent, antihistamine, steroidal or non-steroidal anti-inflammatory agent, anti-parasitic agent, antiviral agent, biostatic composition, chemotherapeutic or antineoplastic agent, cytokine, decongestant, additional hemostatic agent, immunosuppressor, mucolytic, nucleic acid, peptide, protein, steroid, vasoconstrictor, vitamin or mixture thereof.

13. An artificial scab comprising an inhomogeneous, uncohesive, solid sheet-like body contacting an adenoidectomy, tonsillectomy or uvulopalatopharyngoplasty surgical site, the body comprising a granular mixture which when applied is a substantially dry powdered mixture with a water content of less than 10 wt. %, the granular mixture comprising about 10 to about 90 wt. % chitosan particles and about 90 to about 10 wt. % polysaccharide particles adhered to one another by an inter-particle reaction of amino groups on the chitosan particles with aldehyde groups on the polysaccharide particles, the body having an inhomogeneous surface appearance and an inhomogeneous internal structure that breaks apart into smaller pieces when peeled away from the surgical site.

14. An artificial scab according to claim 13 wherein the surgical site is a tonsillectomy site.

15. An artificial scab according to claim 13 having a residence time greater than 1 day.

16. An artificial scab according to claim 13 having a residence time greater than 3 days.

17. An artificial scab according to claim 13 having a residence time less than 2 weeks.

18. A composition according to claim 1 wherein the solid sheet-like body is not a hydrogel.

19. A composition according to claim 1 wherein the solid sheet-like body is not a translucent or transparent liquid covering.

20. An artificial scab according to claim 13 wherein the solid sheet-like body is not a hydrogel.

21. An artificial scab according to claim 13 wherein the solid sheet-like body is not a translucent or transparent liquid covering.

22. A composition according to claim 1 wherein upon application of the mixture to the surgical site or wound the chitosan particles and polysaccharide particles become adhered both to tissue in the surgical site or wound and to one another.

23. A composition according to claim 1 wherein upon application of the mixture to the surgical site or wound the chitosan particles and polysaccharide particles become at least partially solvated and at least partially react with one another.

24. A composition according to claim 1 wherein upon application of the mixture to the surgical site or wound the chitosan particles and polysaccharide particles do not all become fully solvated, and instead retain at least part of the central portion of their original particulate structure in solid, undissolved form.

Assignees

• Hissong James Britton
• Myntti Matthew F
• Medina Jennifer G
• Medtronic Inc

Inventors

• Hissong James Britton
• Myntti Matthew F
• Medina Jennifer G

Classifications

• A61P41/00

  Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution · CPC title

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P35/00

  Antineoplastic agents · CPC title